Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federica Perrone

Showing results (111-120 of 160) with videos related to

Pageof 16
Sort By:
Cancer Biology & Therapy|September 13, 2013
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacyFilippo Pietrantonio, Federica Perrone, Pamela Biondani, et al.
Oncotarget|October 6, 2016
Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition frameworkFabio Bozzi, Silvia Brich, Gian Paolo Dagrada, et al.
Cancer Discovery|June 22, 2016
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal CancerFilippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, et al.
Investigational New Drugs|February 14, 2016
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancerAndrea Necchi, Salvatore Lo Vullo, Luigi Mariani, et al.
The Oncologist|June 22, 2014
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxomaFilippo Pietrantonio, Claudia Maggi, Giuseppe Fanetti, et al.
BJU International|September 19, 2017
First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 studyAndrea Necchi, Salvatore Lo Vullo, Federica Perrone, et al.
Urologic Oncology|September 16, 2017
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 studyAndrea Necchi, Salvatore Lo Vullo, Daniele Raggi, et al.
Oral Oncology|March 9, 2019
A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypesLoris De Cecco, Mara Serena Serafini, Carla Facco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2024
Active Surveillance in Patients with Extra-abdominal Desmoid-Type Fibromatosis: A Pooled Analysis of Three Prospective Observational StudiesChiara Colombo, Stefanie Hakkesteegt, Axel Le Cesne, et al.
Clinical Colorectal Cancer|August 8, 2021
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer PatientsRoberto Moretto, Daniele Rossini, Iolanda Capone, et al.
Pageof 16

Showing results (111-120 of 160) with videos related to

Sort By:
Pageof 16
Cancer Biology & Therapy|September 13, 2013
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacyFilippo Pietrantonio, Federica Perrone, Pamela Biondani, et al.
Oncotarget|October 6, 2016
Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition frameworkFabio Bozzi, Silvia Brich, Gian Paolo Dagrada, et al.
Cancer Discovery|June 22, 2016
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal CancerFilippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, et al.
Investigational New Drugs|February 14, 2016
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancerAndrea Necchi, Salvatore Lo Vullo, Luigi Mariani, et al.
The Oncologist|June 22, 2014
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxomaFilippo Pietrantonio, Claudia Maggi, Giuseppe Fanetti, et al.
BJU International|September 19, 2017
First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 studyAndrea Necchi, Salvatore Lo Vullo, Federica Perrone, et al.
Urologic Oncology|September 16, 2017
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 studyAndrea Necchi, Salvatore Lo Vullo, Daniele Raggi, et al.
Oral Oncology|March 9, 2019
A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypesLoris De Cecco, Mara Serena Serafini, Carla Facco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2024
Active Surveillance in Patients with Extra-abdominal Desmoid-Type Fibromatosis: A Pooled Analysis of Three Prospective Observational StudiesChiara Colombo, Stefanie Hakkesteegt, Axel Le Cesne, et al.
Clinical Colorectal Cancer|August 8, 2021
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer PatientsRoberto Moretto, Daniele Rossini, Iolanda Capone, et al.
Pageof 16